Ken Griffin Actinium Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,200 shares of ATNM stock, worth $63,448. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,200
Previous 45,200
8.85%
Holding current value
$63,448
Previous $56,000
17.86%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ATNM
# of Institutions
66Shares Held
7.6MCall Options Held
51.9KPut Options Held
6.2K-
Black Rock Inc. New York, NY1.88MShares$2.89 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$2.42 Million0.0% of portfolio
-
State Street Corp Boston, MA645KShares$993,6310.0% of portfolio
-
Acadian Asset Management LLC Boston, MA492KShares$757,5920.0% of portfolio
-
Ubs Group Ag396KShares$610,0490.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $38.8M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...